Skip to main content
Premium Trial:

Request an Annual Quote

LGC Biosearch Technologies Gets FDA Emergency Use Authorization for SARS-CoV-2 Test

This article has been updated from a previous version to clarify language about the March 2020 authorization granted to kits supplied by LGC Biosearch.

NEW YORK — The US Food and Drug Administration on Thursday granted Emergency Use Authorization for a PCR-based SARS-CoV-2 test developed by LGC Biosearch Technologies, a Petaluma, California-based division of UK-headquartered LGC.

The Biosearch Technologies SARS-CoV-2 Real-Time and End-Point RT-PCR Test is designed to detect the N gene of the virus in samples collected by a healthcare provider, including anterior nasal, midturbinate nasal, nasopharyngeal, or oropharyngeal swabs, as well as nasopharyngeal washes/aspirates or nasal aspirates. It runs on LGC Biosearch's IntelliQube qPCR instrument.

The test may be used by any lab CLIA-certified to perform high-complexity tests, according to the FDA.

In March 2020, LGC Biosearch Technologies noted that it was supplying Emergency Use Authorized SARS-CoV-2 testing kits developed by the US Centers for Disease Control and Prevention.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more